Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEnterprise ValueEquity AverageEquity RatioInvested CapitalReturn on AssetsReturn on EquityReturn on Sales

Summit Therapeutics (SMMT) EBITDA Margin (2016 - 2024)

Historic EBITDA Margin for Summit Therapeutics (SMMT) over the last 7 years, with Q2 2024 value amounting to 1945.04%.

  • Summit Therapeutics' EBITDA Margin changed N/A to 1945.04% in Q2 2024 from the same period last year, while for Sep 2025 it was 4.95004644540416e19%, marking a year-over-year decrease of 4.95004644540416e23%. This contributed to the annual value of 11131.63% for FY2022, which is 63220700.0% down from last year.
  • Latest data reveals that Summit Therapeutics reported EBITDA Margin of 1945.04% as of Q2 2024.
  • Summit Therapeutics' 5-year EBITDA Margin high stood at 1946.25% for Q1 2020, and its period low was 9742.73% during Q3 2022.
  • In the last 3 years, Summit Therapeutics' EBITDA Margin had a median value of 1668.99% in 2024 and averaged 1114.62%.
  • Examining YoY changes over the last 5 years, Summit Therapeutics' EBITDA Margin showed a top increase of 5211800bps in 2020 and a maximum decrease of 5211800bps in 2020.
  • Summit Therapeutics' EBITDA Margin (Quarter) stood at 1946.25% in 2020, then plummeted by -601bps to 9742.73% in 2022, then skyrocketed by 120bps to 1945.04% in 2024.
  • Its EBITDA Margin was 1945.04% in Q2 2024, compared to 1392.95% in Q1 2024 and 9742.73% in Q3 2022.